Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder.

Soares CN, Fayyad RS, Guico-Pabia CJ.

J Clin Psychopharmacol. 2014 Feb;34(1):57-65. doi: 10.1097/JCP.0000000000000049.

PMID:
24346751
2.

Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.

Soares CN, Endicott J, Boucher M, Fayyad RS, Guico-Pabia CJ.

CNS Spectr. 2014 Dec;19(6):519-27. doi: 10.1017/S1092852914000066. Epub 2014 Feb 26.

PMID:
24571916
3.
4.

BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.

Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:86-91. doi: 10.1016/j.pnpbp.2013.09.016. Epub 2013 Oct 2.

PMID:
24096053
5.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
6.

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.

Liebowitz MR, Tourian KA, Hwang E, Mele L; Study 3362 Investigators.

BMC Psychiatry. 2013 Mar 22;13:94. doi: 10.1186/1471-244X-13-94.

7.
8.

The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.

Kornstein SG, Guico-Pabia CJ, Fayyad RS.

Hum Psychopharmacol. 2014 Sep;29(5):492-501. doi: 10.1002/hup.2427. Epub 2014 Aug 11.

PMID:
25196042
9.

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.

Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.

Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd.

PMID:
23881185
10.
11.

Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.

Iwata N, Tourian KA, Hwang E, Mele L, Vialet C.

J Psychiatr Pract. 2013 Jan;19(1):5-14. doi: 10.1097/01.pra.0000426323.59698.64.

PMID:
23334675
12.

A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.

Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ.

J Womens Health (Larchmt). 2015 Apr;24(4):281-90. doi: 10.1089/jwh.2014.4900.

PMID:
25860107
13.
15.

HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.

Bech P, Boyer P, Germain JM, Padmanabhan K, Haudiquet V, Pitrosky B, Tourian KA.

Pharmacopsychiatry. 2010 Nov;43(7):271-6. doi: 10.1055/s-0030-1263173. Epub 2010 Sep 9.

PMID:
20830664
16.

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA.

Curr Med Res Opin. 2008 Jul;24(7):1877-90. doi: 10.1185/03007990802161923 . Epub 2008 May 27.

PMID:
18507895
17.

Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.

Kornstein SG, Fava M, Jiang Q, Tourian KA.

Psychopharmacol Bull. 2009;42(3):21-35.

PMID:
19752839
18.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
19.

Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Clayton AH, Kornstein SG, Dunlop BW, Focht K, Musgnung J, Ramey T, Bao W, Ninan PT.

J Clin Psychiatry. 2013 Oct;74(10):1010-7. doi: 10.4088/JCP.12m08065.

PMID:
24229754
20.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk